{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:37:42Z","timestamp":1793853462903,"version":"4.6.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Gusu youth medical talent","award":["3101030342000318"],"award-info":[{"award-number":["3101030342000318"]}]},{"name":"Science and education of public health project for young medical talents of Jiangsu Province","award":["QNRC2016747"],"award-info":[{"award-number":["QNRC2016747"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Torsade de pointes (TdP) is a malignant arrhythmia that can be induced by QT internal prolongation due to a variety of factors. Here we report an elderly patient with advanced non-small cell lung cancer (NSCLC) had sudden TdP during hospitalization, which was caused by multiple factors such as osimertinib, moxifloxacin and patient self-factors.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>An 85-year-old man with advanced NSCLC with brain andbone metastasis was initially treated with gefitinib targeted therapy. After 4 months treatment, the patient developed drug resistance and a second genetic testing revealed that the T790M mutation was positive. And the patient was then changed to targeted therapy with osimertinib, followed by adverse reactions of varying severity such as diarrhea, electrolyte imbalance, decreased cardiac function, leukopenia, and prolonged QTc interval. Six months after the administration of osimertinib, the patient was admitted to the hospital, chest CT showed the lesion progressed again, and during which hospital-acquired infection occurred. After concomitant use of moxifloxacin, the patient had sudden TdP, and finally died of this cardiac event.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>It is suggested that clinicians need to identify patients with high risk factors of TdP, and consider comprehensively in concomitant medication to avoid such events to the greatest extent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-01217-4","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T11:02:54Z","timestamp":1592996574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin"],"prefix":"10.1186","volume":"20","author":[{"given":"Shuang","family":"Bian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1392-251X","authenticated-orcid":false,"given":"Wei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"issue":"8","key":"1217_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047\u201360.","journal-title":"Circulation."},{"issue":"5","key":"1217_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/cvr\/cvz013","volume":"115","author":"DM Roden","year":"2019","unstructured":"Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895\u2013903.","journal-title":"Cardiovasc Res"},{"issue":"18","key":"1217_CR3","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","volume":"372","author":"PA Janne","year":"2015","unstructured":"Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689\u201399.","journal-title":"N Engl J Med"},{"issue":"2","key":"1217_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"12","key":"1217_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","volume":"35","author":"JC Yang","year":"2017","unstructured":"Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288\u201396.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1217_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643\u201352.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1217_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2019.01.015","volume":"24","author":"N Colclough","year":"2019","unstructured":"Colclough N, Chen K, Johnstrom P, Friden M, McGinnity DF. Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery. Drug Discov Today. 2019;24(5):1067\u201373.","journal-title":"Drug Discov Today"},{"issue":"2","key":"1217_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181\u201398.","journal-title":"Drug Saf"},{"issue":"7","key":"1217_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ctrv.2015.05.011","volume":"41","author":"YZ Van Sebille","year":"2015","unstructured":"Van Sebille YZ, Gibson RJ, Wardill HR, Bowen JM. ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: chloride secretion as a mechanistic hypothesis. Cancer Treat Rev. 2015;41(7):646\u201352.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1217_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(07)70108-0","volume":"8","author":"S Tejpar","year":"2007","unstructured":"Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JG, Verslype C, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8(5):387\u201394.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1217_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36(5):295\u2013316.","journal-title":"Drug Saf"},{"issue":"2","key":"1217_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.taap.2009.12.032","volume":"244","author":"BB Hasinoff","year":"2010","unstructured":"Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol. 2010;244(2):190\u20135.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"1217_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","volume":"17","author":"F Khan","year":"2018","unstructured":"Khan F, Ismail M, Khan Q, Ali Z. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. Expert Opin Drug Saf. 2018;17(10):1029\u201339.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"1217_CR14","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/cid\/cis664","volume":"55","author":"F Lapi","year":"2012","unstructured":"Lapi F, Wilchesky M, Kezouh A, Benisty JI, Ernst P, Suissa S. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis. 2012;55(11):1457\u201365.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1217_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/sj.bjp.0706389","volume":"146","author":"X Chen","year":"2005","unstructured":"Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, et al. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol. 2005;146(6):792\u20139.","journal-title":"Br J Pharmacol"},{"key":"1217_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1741-7015-12-40","volume":"12","author":"T Cardoso","year":"2014","unstructured":"Cardoso T, Almeida M, Friedman ND, Aragao I, Costa-Pereira A, Sarmento AE, et al. Classification of healthcare-associated infection: a systematic review 10 years after the first proposal. BMC Med. 2014;12:40.","journal-title":"BMC Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01217-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01217-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T23:09:01Z","timestamp":1624489741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01217-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1217"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01217-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]},"assertion":[{"value":"20 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient \u2018s daughter for publication of this case report and any accompanying image.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}